2.24

3.03% -0.07

Aclaris Therapeutics Inc (ACRS)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt ACRS? Forum Prognose

Schlusskurs vom Vortag:

$2.31

Offen:

$2.29

24-Stunden-Volumen:

369.00K

Relative Volume:

0.16

Marktkapitalisierung:

$239.72M

Einnahmen:

$27.08M

Nettoeinkommen (Verlust:

$-37.00M

KGV:

-4.3077

EPS:

-0.52

Netto-Cashflow:

$-18.46M

1W Leistung:

-3.86%

1M Leistung:

-13.85%

6M Leistung:

+76.38%

1J Leistung:

+86.67%

1-Tages-Spanne:

$2.22

$2.335

1-Wochen-Bereich:

$2.22

$2.415

52-Wochen-Spanne:

$0.9515

$5.17

Aclaris Therapeutics Inc Stock (ACRS) Company Profile

Firmenname

Aclaris Therapeutics Inc

Sektor

Healthcare (1169)

Branche

Diagnostics & Research (60)

Telefon

484-324-7933

Adresse

701 LEE ROAD, WAYNE, PA

Mitarbeiter

Twitter

@aclaristx

Nächster Verdiensttermin

2025-02-21

Neueste SEC-Einreichungen

ACRS's Discussions on Twitter

Vergleichen Sie ACRS mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ACRS Aclaris Therapeutics Inc	2.24	239.72M	27.08M	-37.00M	-18.46M	-0.52
TMO Thermo Fisher Scientific Inc	532.55	203.70B	42.88B	6.34B	7.27B	16.53
DHR Danaher Corp	210.23	151.18B	23.88B	3.90B	5.30B	5.28
A Agilent Technologies Inc	135.37	38.62B	6.51B	1.29B	1.37B	4.42
IDXX Idexx Laboratories Inc	452.77	37.07B	3.90B	887.87M	808.08M	10.67
IQV Iqvia Holdings Inc	191.04	33.64B	15.41B	1.37B	2.11B	7.50

Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-12-23	Hochstufung	H.C. Wainwright	Neutral → Buy
2024-11-20	Hochstufung	Cantor Fitzgerald	Neutral → Overweight
2024-11-19	Hochstufung	BTIG Research	Neutral → Buy
2024-11-19	Hochstufung	Jefferies	Hold → Buy
2024-11-19	Hochstufung	Leerink Partners	Market Perform → Outperform
2024-11-18	Hochstufung	Piper Sandler	Neutral → Overweight
2024-01-22	Herabstufung	H.C. Wainwright	Buy → Neutral
2023-11-13	Herabstufung	William Blair	Outperform → Mkt Perform
2023-10-03	Eingeleitet	Evercore ISI	Outperform
2022-12-14	Eingeleitet	Stifel	Buy
2022-12-01	Eingeleitet	Goldman	Buy
2022-10-06	Eingeleitet	BTIG Research	Buy
2021-07-23	Fortgesetzt	Jefferies	Buy
2021-06-15	Eingeleitet	Piper Sandler	Overweight
2021-04-21	Eingeleitet	H.C. Wainwright	Buy
2019-10-22	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2019-09-06	Herabstufung	JMP Securities	Mkt Outperform → Mkt Perform
2019-06-27	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2019-05-06	Eingeleitet	SVB Leerink	Outperform
2018-03-28	Fortgesetzt	Leerink Partners	Outperform
2018-02-09	Eingeleitet	Guggenheim	Buy
2017-06-16	Eingeleitet	Cantor Fitzgerald	Overweight
2016-11-29	Eingeleitet	Leerink Partners	Outperform
2016-09-30	Eingeleitet	JMP Securities	Mkt Outperform
2016-06-10	Eingeleitet	Guggenheim	Buy
2015-11-02	Eingeleitet	Citigroup	Buy
2015-11-02	Eingeleitet	Jefferies	Buy

Alle ansehen

Aclaris Therapeutics Inc Aktie (ACRS) Neueste Nachrichten

Feb 20, 2025

Aclaris Therapeutics (ACRS) Expected to Announce Earnings on Tuesday - MarketBeat

Feb 20, 2025

Common Warts Market to Expand Significantly by 2034, States - openPR

Feb 20, 2025

Feb 18, 2025

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Up 15.6% in January - MarketBeat

Feb 18, 2025

Peapod Lane Capital LLC Takes $1 Million Position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - MarketBeat

Feb 18, 2025

Feb 17, 2025

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Sees Large Growth in Short Interest - Defense World

Feb 17, 2025

Feb 14, 2025

Aclaris Therapeutics Unveils Promising Data on ATI-2138, a Novel Dual ITK/JAK3 Inhibitor - MSN

Feb 14, 2025

Feb 12, 2025

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3 - GlobeNewswire

Feb 12, 2025

Clinical Data: Revolutionary Dual-Target Drug Shows Promise for Multiple Autoimmune Conditions - StockTitan

Feb 12, 2025

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Average Recommendation of “Buy” from Brokerages - Defense World

Feb 12, 2025

Aclaris Therapeutics (NASDAQ:ACRS) Downgraded to "Sell" Rating by StockNews.com - MarketBeat

Feb 12, 2025

Feb 11, 2025

Financial Metrics Check: Aclaris Therapeutics Inc (ACRS)’s Ratios for Trailing Twelve Months - The Dwinnex

Feb 11, 2025

Aclaris Therapeutics: History Of Failures, And Recent Acquisition Of A 'Blockbuster Potential' Molecule - Seeking Alpha

Feb 11, 2025

Feb 10, 2025

What is Leerink Partnrs' Forecast for ACRS FY2029 Earnings? - MarketBeat

Feb 10, 2025

H.C. Wainwright gives a Buy recommendation for Aclaris Therapeutics Inc (ACRS) - Knox Daily

Feb 10, 2025

Leerink Partnrs Has Negative Outlook of ACRS FY2025 Earnings - MarketBeat

Feb 10, 2025

Feb 08, 2025

Research Analysts Issue Forecasts for ACRS FY2029 Earnings - Armenian Reporter

Feb 08, 2025

StockNews.com Downgrades Aclaris Therapeutics (NASDAQ:ACRS) to Sell - Defense World

Feb 08, 2025

Feb 07, 2025